• P M Olaechea Astigarraga, J Garnacho Montero, S Grau Cerrato, O Rodríguez Colomo, M Palomar Martínez, R Zaragoza Crespo, P Muñoz García-Paredes, E Cerdá Cerdá, F Alvarez Lerma, GEIPC-SEIMC, and GTEI-SEMICYUC.
• Servicio de Medicina Intensiva, Hospital de Galdakao, Bo. de Labeaga s/n, 48960 Galdakao, Vizcaya, Spain. pedromaria.olaecheaastigarrag@osakidetza.net
• Med Intensiva. 2007 Aug 1; 31 (6): 294-317.

AbstractIn recent years, an increment of infections caused by gram-positive cocci has been documented in nosocomial and hospital-acquired infections. In diverse countries, a rapid development of resistance to common antibiotics against gram-positive cocci has been observed. This situation is exceptional in Spain but our country might be affected in the near future. New antimicrobials active against these multi-drug resistant pathogens are nowadays available. It is essential to improve our current knowledge about pharmacokinetic properties of traditional and new antimicrobials to maximize its effectiveness and to minimize toxicity. These issues are even more important in critically ill patients because inadequate empirical therapy is associated with therapeutic failure and a poor outcome. Experts representing two scientific societies (Grupo de estudio de Infecciones en el Paciente Critico de la SEIMC and Grupo de trabajo de Enfermedades Infecciosas de la SEMICYUC) have elaborated a consensus document based on the current scientific evidence to summarize recommendations for the treatment of serious infections caused by gram-positive cocci in critically ill patients.

25 keywords...

hide…